Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
7 hedge funds and large institutions have $845K invested in Alexion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 696 closing their positions.
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
99% less funds holding
Funds holding: 710 → 7 (-703)
100% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 696
100% less funds holding in top 10
Funds holding in top 10: 77 → 0 (-77)
100% less capital invested
Capital invested by funds: $39.1B → $845K (-$39.1B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NICM
Neo Ivy Capital Management
New York
|
+$475K |
| 2 |
TAIM
TD Ameritrade Investment Management
Omaha,
Nebraska
|
+$131K |
| 3 |
RG
Retirement Group
San Diego,
California
|
+$9.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.74B |
| 2 |
BlackRock
New York
|
-$3.21B |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.84B |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.42B |
| 5 |
HI
HBK Investments
Dallas,
Texas
|
-$1.21B |
ALXN Hedge Fund Activity: Q3 2021 in Review
7 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2021, worth a combined $845K — down 100% from $39.1B a quarter earlier.
Sellers outnumbered buyers: 696 funds closed out of ALXN and 1 opened new positions — a net loss of 695 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $475K. The largest seller was Vanguard Group, exiting entirely with an estimated $3.74B sold.
- 7 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2021, down from 710 in Q2 2021.
- Funds reported $845K of Alexion Pharmaceuticals stock for Q3 2021, down 100% quarter-over-quarter.
- 1 fund opened new Alexion Pharmaceuticals positions in Q3 2021 and 696 closed out, a net change of -695 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $475K added.
- The largest Alexion Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $3.74B sold.
Based on aggregated 13F filings for Q3 2021.